Locations:
October 27, 2025/Digestive/Research

Tirzepatide Linked to Better Heart Outcomes Than Semaglutide in MASLD, Obesity and Diabetes

Findings could help clinicians make more informed decisions about medication recommendations

Patient holding injectable

A large new study by Cleveland Clinic researchers has found that Tirzepatide is associated with better cardiovascular outcomes than Semaglutide in MASLD patients with obesity and Type 2 diabetes.

Advertisement

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

Cleveland Clinic hepatologist and senior author Dian Chiang, MD, MPH, calls the findings a “critical piece of information” that could help guide treatment decisions. He notes that the new study is the first to compare cardiovascular outcomes for the two drugs in this population.

“We have more and more evidence that these medications do work — not only to help with liver-related outcomes, but also with cardiovascular outcomes,” he says. “And now we have evidence that a dual agonist is better than a single agonist.”

Findings

The study compares real-world liver and cardiovascular outcomes for the two drugs in MASLD patients with obesity, and type 2 diabetes. Using the TriNetX health research network, researchers analyzed data for almost 31,000 adult patients.

Tirzepatide was associated with significantly lower risks of major adverse cardiovascular events, all-cause mortality, and all-cause hospitalizations than Semaglutide. Patients receiving tirzepatide also had lower risks of cardiovascular outcomes like myocardial infarction, heart failure and heart failure exacerbations.

Researchers found no significant differences in liver outcomes like cirrhosis and hepatocellular carcinoma.

Impact on care

Dr. Chiang says the results were not surprising.

“I think this reconfirmed what we have suspected, especially knowing that Trizepatide, because it’s a dual agonist, has a better weight loss and blood sugar control effect compared to GLP-1 only,” he explains.

That doesn’t mean Trizepatide will be the better drug for all patients, he adds, noting that for some patients with MASLD, weight loss that is too rapid could be harmful to the liver.

Advertisement

“This new information will help physicians and patients make an informed decision, but I don’t think the physician will make their recommendation solely on this study alone,” he says.

Looking ahead

As a next step, researchers are conducting a subgroup analysis to understand how different patient cohorts respond to the drugs.

“We want to know which patients will benefit the most from which one, and how we can offer it in a way to maximize the benefit and minimize the complications,” says Dr Chiang. “So, the next stage of clinical research will be identifying factors to help us individualize treatment.”

The study, “Comparative Efficacy of Tirzepatide vs. Semaglutide in Patients with MASLD/MASH, Obesity, and Type 2 Diabetes Mellitus: A Real-World Cohort Study,” will be presented at this year’s American College of Gastroenterology meeting.

Advertisement

Related Articles

A closeup of black blood vessels and large dark spots on a gray background

Do AREDS Vitamins Slow Progression of Geographic Atrophy?

Real-world, OCT-based data show no difference in lesion growth between patients with and without supplementation

Teen and parent embracing
September 1, 2026/Pediatrics/Behavioral health

Why Adolescents With ADHD Need Better Transitions to Adult Care

Early planning can help prevent disruptions in treatment, medication access and support

female hands holding a pharmaceutical injector

GLP-1 RAs Show Survival and Cardiovascular Benefits in Patients With HFrEF and Diabetes

Large retrospective analysis may prompt prospective studies

Dr. Aminian in OR
May 7, 2026/Digestive/Research

Metabolic Surgery May Reverse MASH Cirrhosis, Paired Biopsy Study Suggests

Research demonstrates cirrhosis regression in one-third of patients, with higher rates using alternative assessment

Fundus image of diabetic retinopathy

AI-Powered Fundus Cameras Diagnose Diabetic Retinopathy in Seconds

New service for patients with diabetes will make annual screening more convenient

Patient holding injectable
March 26, 2026/Digestive/Research

New Analysis Examines Long-Term Outcomes of GLP-1 Therapies in Type 1 Diabetes

Retrospective analysis finds lower mortality rates, fewer hospital visits among patients with Type 1 diabetes using GLP-1 Therapies

yellow and white pills strewn on a dark countertop
February 3, 2026/Primary Care

ACE Inhibitors and ARBs Before Noncardiac Surgery: To Hold or Not to Hold?

Emerging evidence suggests a patient-specific approach

Patient injecting herself
January 12, 2026/Pulmonary/News & Insight

Advances in COPD Treatment: The Role of Biologics

Looking at the real-world impact and the future pipeline of targeted therapies

Ad